Genmab A/S / ProfoundBio Inc.

Ovarian Cancer (FRα-Positive)

20K US cases/yr · $3.5B Global Ovarian Cancer Market (2025E)

Disease Overview

Rina-S is a potential best-in-class FRα-targeted Topo1 ADC. 55.6% confirmed ORR in heavily pretreated platinum-resistant OvCa, DOR not reached. 50% ORR in endometrial cancer. FDA Fast Track.

Competitive Landscape

Competes with AbbVie Elahere for FRα+ OvCa. Rina-S uses Topo1 vs Elahere DM4. Genmab building ADC commercial capability. Pruned other acquired programs to focus on Rina-S.

Solid Tumors (SLITRK6)

Competitive Landscape

GEN1106 (PRO1106) is a Phase 1 SLITRK6-targeted ADC primarily positioned for urothelial carcinoma and other SLITRK6-expressing solid tumors. The competitive landscape groups by MOA class: SLITRK6-targeted ADCs (direct, sparse), Nectin-4 ADCs (leading urothelial franchise), HER2 ADCs (urothelial crossover), and FGFR3-targeted agents. In the direct SLITRK6 ADC class, Astellas/Seagen's sirtratumab vedotin (ASG-15ME, MMAE payload) was the first-in-class SLITRK6 ADC but was discontinued after Phase 1 in urothelial carcinoma, leaving GEN1106 as effectively the sole active clinical-stage asset and meaning the target itself is commercially unvalidated. In the Nectin-4 ADC class, Seagen/Astellas/Pfizer's Padcev (enfortumab vedotin, approved 2019 urothelial, combined with pembrolizumab as first-line standard per EV-302, approximately $1.6B 2024 sales) is the dominant urothelial franchise and the critical share anchor. In the HER2 ADC class, AstraZeneca/Daiichi's Enhertu (trastuzumab deruxtecan) has pan-tumor activity in HER2-expressing urothelial via DESTINY-PanTumor02. In the FGFR inhibitor class, J&J's Balversa (erdafitinib, approved 2019) serves FGFR3-altered urothelial. TROP2 ADCs (Gilead's Trodelvy, sacituzumab govitecan) previously held urothelial indication withdrawn 2024. Commercial takeaway: SLITRK6 is an unvalidated target with one prior failed clinical asset; GEN1106 is a high-risk/high-option platform bet rather than a near-term franchise threat.

Endometrial Cancer (FRa-Positive)

Competitive Landscape

Rinatabart sesutecan (Rina-S) is an FRa-targeted topoisomerase 1 inhibitor (exatecan payload) ADC in Phase 2/3 development for endometrial cancer and ovarian cancer. The competitive landscape groups by MOA class: FRa-targeted ADCs (direct), TROP2 and HER2 ADCs crossing over to endometrial, immunotherapy-anchored standards, and targeted agents. In the FRa-targeted ADC class, AbbVie's Elahere (mirvetuximab soravtansine, DM4 payload, FDA-approved 2022 accelerated then 2024 full approval for FRa-high platinum-resistant ovarian cancer, approximately $480M 2024 sales) is the incumbent and the direct read-across comparator; endometrial cancer expansion studies are ongoing. Sutro Biopharma's luveltamab tazevibulin (STRO-002, hemiasterlin payload, Phase 2/3 REFRaME) is the other late-stage FRa ADC. In crossover ADCs, AstraZeneca/Daiichi's Enhertu (trastuzumab deruxtecan) has activity in HER2-expressing endometrial (DESTINY-PanTumor02) and Gilead's Trodelvy (sacituzumab govitecan, TROP2) is investigated. In immunotherapy, Merck's Keytruda (pembrolizumab) + Eisai's Lenvima (lenvatinib) is approved for advanced endometrial and the Jemperli (dostarlimab, GSK) + carboplatin/paclitaxel combination (RUBY trial) received 2024 FDA approval for primary advanced/recurrent endometrial, establishing a new frontline standard. Commercial takeaway: Rina-S must carve space behind Elahere in ovarian and against dMMR IO backbones in endometrial; exatecan payload differentiation is the critical battleground.